DadFinStart your free week
DadFin › Stocks › Healthcare › TEVA

Teva Pharmaceutical Industries Lim (TEVA) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Israel

$41.10 ▲ +4.71% today

93.6
Dad Score, out of 100
strong

Teva Pharmaceutical Industries Lim (TEVA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Israel. On DadFin's weekly run it scores 93.6 out of 100 on the Dad Score, a strong reading that places the business ahead of 94% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #57 of 974. Its strongest axes are valuation, quality and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Strong
Growth
Average
Price action
Strong
Risk
Average
Conviction
Above average
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)65.9×
P/E (forward)12.8×
Dividend yield0.00%
Return on capital7.9%
Operating margin4.0%
Revenue growth (YoY)+4.3%
FCF yield1.9%
Net debt / EBITDA3.10×
Piotroski F-Score8 / 9
52-week change+98.1%
Market cap$46.1B
Next earningsNov 3, 2026

What subscribers see on TEVA

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B
RDYDr. Reddy's Laboratories Limited28.5weak$10.2B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.